The Financial Results for the year ended 31-03-2025 are attached herewith.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hamps Bio Ltd reported FY25 revenue from operations of ₹666.87 lakhs, up modestly from ₹647.52 lakhs in FY24 (about 3% growth). However, profit after tax declined sharply to ₹29.77 lakhs from ₹50.06 lakhs in FY24, a drop of roughly 40%, as total expenses rose faster than revenue (₹641.60 lakhs vs ₹585.13 lakhs). EPS fell to ₹0.68 from ₹2.55. Statutory auditor M/s MGVS & Associates issued an unmodified (clean) opinion on the results. The company, which got listed on BSE SME in December 2024, has utilised ₹438.34 lakhs of IPO proceeds mainly for plant and machinery and brand building, with ₹183.86 lakhs still unutilised and parked in fixed deposits.
Margins came under pressure with expenses growing faster than revenue, leading to a significant fall in profits, which is a negative signal for near-term earnings. The clean audit opinion and ongoing capex-driven expansion provide some comfort, but shareholders should watch for revenue acceleration to justify the post-IPO spending.